Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours

We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tovey, S M, Brown, S, Doughty, J C, Mallon, E A, Cooke, T G, Edwards, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653773/
https://www.ncbi.nlm.nih.gov/pubmed/19223897
http://dx.doi.org/10.1038/sj.bjc.6604940
Descripción
Sumario:We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab.

Ejemplares similares